Clinical trial · Interventional
A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis
Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU)
NCT00149201CI-TRIAL-00001968completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To develop effective chemotherapy regimen against gastric cancer with peritoneal metastasis
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Neoplasm Metastasis | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-FU continuous infusion | Drug | — | UNRESOLVED |
| MTX + 5-FU sequential therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall survival
Secondary outcomes (2)
- measure
- oral intake
- measure
- toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. histologic confirmation of gastric adenocarcinoma 2. inoperable metastatic disease or recurrent metastatic disease after surgery 3. disease with peritoneal metastasis 4. 20 years or more but less than 75 years 5. performance status 2 or less on the Eastern Cooperative Oncology Group scale 6. no prior treatment for gastric carcinoma except for surgery and adjuvant chemotherapy 7. no prior chemotherapy or radiotherapy for other disease except for gastric cancer 8. adequate bone marrow function, adequate liver function, and adequate renal function 9. no prior transfusion for anemia 10. provision of written informed consent Exclusion Criteria: 1. Massive pleural effusion 2. brain metastasis with symptoms 3. severe diarrhea 4. other severe medical conditions (infection, diabetes, hypertension, acute myocardial infarction, unstable angina, liver cirrhosis, intestinal pneumonia, pulmonary fibrosis) 5. other active malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.